Suppr超能文献

使用免疫抑制剂治疗再生障碍性贫血。

Treatment of aplastic anemia with immunosuppressive agents.

作者信息

Takaku F

机构信息

Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

出版信息

Tokai J Exp Clin Med. 1986;11 Suppl:197-204.

PMID:3452242
Abstract

184 cases of aplastic anemia were treated by various immunosuppressive agents. 25.1% of the 35 patients with moderately severe aplastic anemia showed a hematological response to bolus methylprednisolone m PSL treatment. 9.6% of 73, 16.9% of 65 and 42.9% of 14 cases with severe aplastic anemia responded to m PSL, anti-lymphocyte globulin and anti-thymocyte globulin treatment, respectively. There was no difference in the survival of these severe aplastic anemia patients, however, which were prolonged invariably by treatment with each of these immunosuppressive agents. No correlation was observed between the in vitro increase of hematopoietic cell colony growth of the patient's bone marrow and clinical response to the immunosuppressive agents.

摘要

184例再生障碍性贫血患者接受了各种免疫抑制剂治疗。35例中度重型再生障碍性贫血患者中,25.1%对大剂量甲基强的松龙(mPSL)治疗有血液学反应。73例重型再生障碍性贫血患者中9.6%、65例中16.9%以及14例中42.9%分别对mPSL、抗淋巴细胞球蛋白和抗胸腺细胞球蛋白治疗有反应。然而,这些重型再生障碍性贫血患者的生存率并无差异,不过,每种免疫抑制剂治疗均能使生存率延长。未观察到患者骨髓造血细胞集落生长的体外增加与免疫抑制剂临床反应之间存在相关性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验